10 June 2020 : Case report
Empagliflozin-Mediated Lithium Excretion: A Case Study and Clinical Applications
Unusual or unexpected effect of treatment, Adverse events of drug therapy
Guy Philip Armstrong1ABCDEFG*DOI: 10.12659/AJCR.923311
Am J Case Rep 2020; 21:e923311
Abstract
BACKGROUND: Empagliflozin selectively reduces apical sodium-glucose co-transporter 2 function in the proximal convoluted tubules, increasing sodium and glucose excretion in the urine, ultimately reducing glucose reabsorption in the kidneys for diabetic management. Lithium, the gold-standard treatment for bipolar disorder, also utilizes sodium transporters in the proximal convoluted tubules.
CASE REPORT: Presenting with a manic relapse of refractory schizoaffective disorder, our patient was found to have subtherapeutic levels of lithium on admission due to poor outpatient medication compliance. Restoration to therapeutic lithium levels allowed inpatient blood glucose measurements, which led to a new diagnosis of type 2 diabetes mellitus. Given his comorbid severe hepatic impairment, obesity, and prior pancreatitis, the patient was started on empagliflozin to safely manage this new diagnosis without collateral organ injury. Routine monitoring found reproducible and clinically significant decreases in serum lithium levels in the presence of empagliflozin therapy, without obvious confounding factors. Subsequent discussion with specialist teams resulted in trialling metformin, which adequately controlled the new diabetic diagnosis without inpatient complications.
CONCLUSIONS: We suspect that empagliflozin reduced sodium-glucose and lithium-glucose reabsorption in the proximal connecting tubules, thereby increasing the renal excretion of sodium, glucose, and lithium. Applications include awareness of the interaction between these medications, support for the role of physiological SGLT-2-mediated lithium transport, and the possibility of using empagliflozin and other SGLT-2 inhibitors to treat life-threatening lithium toxicity.
Keywords: Drug Interactions, Lithium, Sodium-Glucose Transporter 2, Renal Excretion, Antimanic Agents, Benzhydryl Compounds, Diabetes Mellitus, Type 2, Glucosides, Hypoglycemic Agents, Lithium Compounds, medication adherence, Metformin, Psychotic Disorders, Sodium-Glucose Transporter 2 Inhibitors
In Press
Case report
Acalculous Cholecystitis as an Atypical Presentation of Viral Pericarditis: A Case ReportAm J Case Rep In Press; DOI: 10.12659/AJCR.946029
Case report
Perforating Internal Root Resorption Sealed with Single-Cone Technique Using Bioceramic Sealer: A Case ReportAm J Case Rep In Press; DOI: 10.12659/AJCR.946838
Case report
Concurrent Meckel’s Diverticulum and Sjögren Syndrome: A Case of Intestinal ObstructionAm J Case Rep In Press; DOI: 10.12659/AJCR.945640
Case report
Resistant Renovascular Hypertension in Youth: Fibromuscular Dysplasia or Takayasu Arteritis?Am J Case Rep In Press; DOI: 10.12659/AJCR.945673
Most Viewed Current Articles
21 Jun 2024 : Case report 82,012
Intracranial Parasitic Fetus in a Living Infant: A Case Study with Surgical Intervention and Prognosis Anal...DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report 48,655
Neurocysticercosis Presenting as Migraine in the United StatesDOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
20 Nov 2023 : Case report 22,726
Azithromycin Treatment for Acne Vulgaris: A Case Report on the Risk of Clostridioides difficile InfectionDOI :10.12659/AJCR.941424
Am J Case Rep 2023; 24:e941424
07 Jul 2023 : Case report 19,595
A Classical Case of Cesarean Scar Endometriosis in a 35-Year-Old Woman Presenting with Cyclical Abdominal P...DOI :10.12659/AJCR.940200
Am J Case Rep 2023; 24:e940200